Literature DB >> 34330959

Validation of nasospheroids to assay CFTR functionality and modulator responses in cystic fibrosis.

Silvia Gartner1, Eduardo F Tizzano2,3, Maite Calucho4,5, Paula Barranco4,5, Paula Fernández-Álvarez4,5, Raquel García Pérez6.   

Abstract

The availability of a simple, robust and non-invasive in vitro airway model would be useful to study the functionality of the cystic fibrosis transmembrane regulator (CFTR) protein and to personalize modulator therapy for cystic fibrosis (CF) patients. Our aim was to validate a CFTR functional study using nasospheroids, a patient-derived nasal cell 3D-culture. We performed live-cell experiments in nasospheroids obtained from wild-type individuals and CF patients with different genotypes and phenotypes. We extended the existing method and expanded the analysis to upgrade measurements of CFTR activity using forskolin-induced shrinking. We also tested modulator drugs in CF samples. Immobilizing suspended-nasospheroids provided a high number of samples for live-cell imaging. The diversity observed in basal sizes of nasospheroids did not affect the functional analysis of CFTR. Statistical analysis with our method was simple, making this protocol easy to reproduce. Moreover, we implemented the measurement of inner fluid reservoir areas to further differentiate CFTR functionality. In summary, this rapid methodology is helpful to analyse response to modulators in CF samples to allow individualized treatment for CF patients.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34330959     DOI: 10.1038/s41598-021-94798-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  34 in total

Review 1.  Progress in therapies for cystic fibrosis.

Authors:  Kris De Boeck; Margarida D Amaral
Journal:  Lancet Respir Med       Date:  2016-04-01       Impact factor: 30.700

2.  Identification of the cystic fibrosis gene: genetic analysis.

Authors:  B Kerem; J M Rommens; J A Buchanan; D Markiewicz; T K Cox; A Chakravarti; M Buchwald; L C Tsui
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

3.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.

Authors:  Peter G Middleton; Marcus A Mall; Pavel Dřevínek; Larry C Lands; Edward F McKone; Deepika Polineni; Bonnie W Ramsey; Jennifer L Taylor-Cousar; Elizabeth Tullis; François Vermeulen; Gautham Marigowda; Charlotte M McKee; Samuel M Moskowitz; Nitin Nair; Jessica Savage; Christopher Simard; Simon Tian; David Waltz; Fengjuan Xuan; Steven M Rowe; Raksha Jain
Journal:  N Engl J Med       Date:  2019-10-31       Impact factor: 91.245

4.  Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.

Authors:  Jennifer L Taylor-Cousar; Manu Jain; Tara Lynn Barto; Tarik Haddad; Jeffrey Atkinson; Simon Tian; Rui Tang; Gautham Marigowda; David Waltz; Joseph Pilewski
Journal:  J Cyst Fibros       Date:  2017-11-08       Impact factor: 5.482

5.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

Authors:  Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Jeffrey H Stack; Kimberly S Straley; Caroline J Decker; Mark Miller; Jason McCartney; Eric R Olson; Jeffrey J Wine; Ray A Frizzell; Melissa Ashlock; Paul A Negulescu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-05       Impact factor: 11.205

6.  A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.

Authors:  Seth Walker; Patrick Flume; John McNamara; Melinda Solomon; Mark Chilvers; James Chmiel; R Scott Harris; Eric Haseltine; David Stiles; Chonghua Li; Neil Ahluwalia; Honghong Zhou; Caroline A Owen; Gregory Sawicki
Journal:  J Cyst Fibros       Date:  2019-06-26       Impact factor: 5.482

7.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.

Authors:  Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Dong Cao; Tim Neuberger; Amanda Turnbull; Ashvani Singh; John Joubran; Anna Hazlewood; Jinglan Zhou; Jason McCartney; Vijayalaksmi Arumugam; Caroline Decker; Jennifer Yang; Chris Young; Eric R Olson; Jeffery J Wine; Raymond A Frizzell; Melissa Ashlock; Paul Negulescu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-21       Impact factor: 11.205

8.  Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.

Authors:  John J McNamara; Susanna A McColley; Gautham Marigowda; Fang Liu; Simon Tian; Caroline A Owen; David Stiles; Chonghua Li; David Waltz; Linda T Wang; Gregory S Sawicki
Journal:  Lancet Respir Med       Date:  2019-01-24       Impact factor: 30.700

9.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Authors:  Harry G M Heijerman; Edward F McKone; Damian G Downey; Eva Van Braeckel; Steven M Rowe; Elizabeth Tullis; Marcus A Mall; John J Welter; Bonnie W Ramsey; Charlotte M McKee; Gautham Marigowda; Samuel M Moskowitz; David Waltz; Patrick R Sosnay; Christopher Simard; Neil Ahluwalia; Fengjuan Xuan; Yaohua Zhang; Jennifer L Taylor-Cousar; Karen S McCoy
Journal:  Lancet       Date:  2019-10-31       Impact factor: 79.321

Review 10.  Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.

Authors:  Marie E Egan
Journal:  Curr Opin Pediatr       Date:  2020-06       Impact factor: 2.856

View more
  1 in total

Review 1.  Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis.

Authors:  Iris A L Silva; Onofrio Laselva; Miquéias Lopes-Pacheco
Journal:  J Pers Med       Date:  2022-08-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.